Correlations between Immune Response and Etiopathogenic Factors of Medication-Related Osteonecrosis of the Jaw in Cancer Patients Treated with Zoledronic Acid
暂无分享,去创建一个
A. Camen | S. Popescu | M. Scrieciu | R. Mercuț | Mihaela Ionescu | GEORGE-ADRIAN Ciobanu | Ionela Elisabeta Staicu | Laurențiu Mogoantă | Cristina Maria Munteanu | C. Georgescu | Daniel Vlad
[1] L. Chivu,et al. Risk Factors for Medication-Related Osteonecrosis of the Jaw—A Binomial Analysis of Data of Cancer Patients from Craiova and Constanta Treated with Zoledronic Acid , 2023, Journal of clinical medicine.
[2] L. Mogoantă,et al. Clinical and Histopathological Aspects of MRONJ in Cancer Patients , 2023, Journal of clinical medicine.
[3] F. Mussano,et al. Immune Dysfunction in Medication-Related Osteonecrosis of the Jaw , 2023, International journal of molecular sciences.
[4] S. Olate,et al. Medication-Related Osteonecrosis of the Jaws (MRONJ) in Children and Young Patients—A Systematic Review , 2023, Journal of clinical medicine.
[5] Hiroko Wada,et al. Actin alpha 2, smooth muscle, a transforming growth factor-β1-induced factor, regulates collagen production in human periodontal ligament cells via Smad2/3 pathway. , 2022, Journal of dental sciences.
[6] A. Giannì,et al. Medication-Related Osteonecrosis of the Jaw in Dental Practice: A Retrospective Analysis of Data from the Milan Cohort , 2022, Dentistry journal.
[7] S. Park,et al. Effects of Type 2 Diabetes Mellitus on Osteoclast Differentiation, Activity, and Cortical Bone Formation in POSTmenopausal MRONJ Patients , 2022, Journal of clinical medicine.
[8] N. Park,et al. Indigenous microbiota protects development of medication-related osteonecrosis induced by periapical disease in mice , 2022, International journal of oral science.
[9] G. Campisi,et al. One changing and challenging scenario: the treatment of cancer patients with bone metastases by bisphosphonates and denosumab, the cost–benefit evaluation of different options, and the risk of medication-related osteonecrosis of the jaw (MRONJ) , 2022, Supportive Care in Cancer.
[10] F. Bertoldo,et al. The preventive care of medication-related osteonecrosis of the jaw (MRONJ): a position paper by Italian experts for dental hygienists , 2022, Supportive Care in Cancer.
[11] C. Dobó-Nagy,et al. Targeted histological evaluation shows high incidence of actinomyces infection in medication-related osteonecrosis of the jaws , 2022, Scientific Reports.
[12] N. Chattipakorn,et al. Impacts of bisphosphonates on the bone and its surrounding tissues: mechanistic insights into medication-related osteonecrosis of the jaw , 2022, Archives of Toxicology.
[13] K. Miyamoto,et al. Osteonecrosis development by tooth extraction in zoledronate treated mice is inhibited by active vitamin D analogues, anti-inflammatory agents or antibiotics , 2022, Scientific reports.
[14] S. Tetradis,et al. Macrophage Involvement in Medication-Related Osteonecrosis of the Jaw (MRONJ): A Comprehensive, Short Review , 2022, Cancers.
[15] E. C. Sung,et al. Mechanism of bisphosphonate-related osteonecrosis of the jaw (BRONJ) revealed by targeted removal of legacy bisphosphonate from jawbone using competing inert hydroxymethylene diphosphonate , 2021, medRxiv.
[16] A. Gaudio,et al. Early Changes of VEGF Levels After Zoledronic Acid in Women With Postmenopausal Osteoporosis: A Potential Role of Vitamin D , 2021, Frontiers in Medicine.
[17] H. Y. Kim. Review and Update of the Risk Factors and Prevention of Antiresorptive-Related Osteonecrosis of the Jaw , 2021, Endocrinology and metabolism.
[18] S. Abrams,et al. Discovering Myeloid Cell Heterogeneity in Mandibular Bone – Cell by Cell Analysis , 2021, Frontiers in Physiology.
[19] P. Gándara-Vila,et al. Medication-Related Osteonecrosis of the Jaw: A Critical Narrative Review , 2021, Journal of clinical medicine.
[20] C. Giachelli,et al. Engineered Osteoclasts Resorb Necrotic Alveolar Bone in Anti-RANKL Antibody-Treated Mice. , 2021, Bone.
[21] M. Ehrenfeld,et al. Infection as an Important Factor in Medication-Related Osteonecrosis of the Jaw (MRONJ) , 2021, Medicina.
[22] Byoung-Eun Yang,et al. Various Therapeutic Methods for the Treatment of Medication-Related Osteonecrosis of the Jaw (MRONJ) and Their Limitations: A Narrative Review on New Molecular and Cellular Therapeutic Approaches , 2021, Antioxidants.
[23] S. Popescu,et al. Mandibulectomy Reconstruction with Pectoralis Major Island Flap Associated with Primary Reconstruction Plate for Mandibular Medication-Related Osteonecrosis , 2021, Current health sciences journal.
[24] A. Munz,et al. Microarchitecture of medication-related osteonecrosis of the jaw (MRONJ); a retrospective micro-CT and morphometric analysis. , 2021, Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery.
[25] Ling Gao,et al. The Role of the Immune Response in the Development of Medication-Related Osteonecrosis of the Jaw , 2021, Frontiers in Immunology.
[26] Li-Hang Shen,et al. Exosomes from Adipose-Derived Stem Cells Can Prevent Medication-Related Osteonecrosis of the Jaw , 2021, Medical science monitor : international medical journal of experimental and clinical research.
[27] J. Yates,et al. Systematic review of medication related osteonecrosis of the jaw (MRONJ) in patients undergoing only antiangiogenic drug therapy: surgery or conservative therapy? , 2020, The British journal of oral & maxillofacial surgery.
[28] C. Moinpour,et al. Association of Osteonecrosis of the Jaw With Zoledronic Acid Treatment for Bone Metastases in Patients With Cancer. , 2020, JAMA oncology.
[29] F. Baudi,et al. The Case of Medication-Related Osteonecrosis of the Jaw Addressed from a Pathogenic Point of View. Innovative Therapeutic Strategies: Focus on the Most Recent Discoveries on Oral Mesenchymal Stem Cell-Derived Exosomes , 2020, Pharmaceuticals.
[30] Y. Niu,et al. Pathogenesis and multidisciplinary management of medication-related osteonecrosis of the jaw , 2020, International journal of oral science.
[31] F. Baudi,et al. Dose-Dependent Effects of Zoledronic Acid on Human Periodontal Ligament Stem Cells: An In Vitro Pilot Study , 2020, Cell transplantation.
[32] H. Essig,et al. Antimicrobial peptide gene expression in medication-related osteonecrosis of the jaw. , 2020, Pathology, research and practice.
[33] K. Pereira,et al. Bisphosphonate-related osteonecrosis induced change in alveolar bone architecture in rats with participation of Wnt signaling , 2020, Clinical Oral Investigations.
[34] P. Vescovi,et al. Medication-Related Osteonecrosis of Jaws (MRONJ) Prevention and Diagnosis: Italian Consensus Update 2020 , 2020, International journal of environmental research and public health.
[35] M. Siddique,et al. Teriparatide Promotes Bone Healing in Medication-Related Osteonecrosis of the Jaw: A Placebo-Controlled, Randomized Trial. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] B. Hutton,et al. Long-term impact of bone-modifying agents for the treatment of bone metastases: a systematic review , 2020, Supportive Care in Cancer.
[37] M. Bornstein,et al. Medication-related osteonecrosis of the jaws (MRONJ) in cancer patients treated with denosumab VS. zoledronic acid: A systematic review and meta-analysis , 2020, Medicina oral, patologia oral y cirugia bucal.
[38] M. Osaki,et al. Bisphosphonates induced reactive oxygen species inhibit proliferation and migration of oral fibroblast: A pathogenesis of bisphosphonate-related osteonecrosis of the Jaw. , 2019, Journal of periodontology.
[39] Wenjie Zhang,et al. Decreased osteogenic ability of periodontal ligament stem cells leading to impaired periodontal tissue repair in BRONJ patients. , 2019, Stem cells and development.
[40] N. Yarom,et al. Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] Nicole M. Chapman,et al. Helper T cell differentiation , 2019, Cellular & Molecular Immunology.
[42] George Bullock. Tissue engineering approaches to the treatment of bisphosphonate-related osteonecrosis of the jaw , 2019 .
[43] K. Roszkowski,et al. Biphosphonates-related osteonecrosis of the jaw , 2019, Medical Research Journal.
[44] M. Iriti,et al. Development and validation of a method using ultra performance liquid chromatography coupled to tandem mass spectrometry for determination of zoledronic acid concentration in human bone , 2019, Journal of pharmaceutical and biomedical analysis.
[45] C. Pautke,et al. Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases. , 2018, Cancer treatment reviews.
[46] A. E. Hakam,et al. Current Understanding of the Pathophysiology of Osteonecrosis of the Jaw , 2018, Current Osteoporosis Reports.
[47] S. Patntirapong,et al. Alteration of macrophage viability, differentiation, and function by bisphosphonates. , 2018, Oral diseases.
[48] S. Ivanovski,et al. Risk factors for medication-related osteonecrosis of the jaws: A systematic review. , 2018, Oral diseases.
[49] G. Garlet,et al. RANKL Triggers Treg-Mediated Immunoregulation in Inflammatory Osteolysis , 2018, Journal of dental research.
[50] C. Politis,et al. Microbial population changes in patients with medication-related osteonecrosis of the jaw treated with systemic antibiotics. , 2017, Oral surgery, oral medicine, oral pathology and oral radiology.
[51] J. Konkel,et al. Tissue-Specific Immunity at the Oral Mucosal Barrier. , 2017, Trends in immunology.
[52] G. Dryden,et al. Immunopathophysiology of inflammatory bowel disease: how genetics link barrier dysfunction and innate immunity to inflammation , 2017, Innate immunity.
[53] S. Kalyan. It May Seem Inflammatory, but Some T Cells Are Innately Healing to the Bone , 2016, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[54] A. Neff,et al. Impact of Soft Tissue Pathophysiology in the Development and Maintenance of Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) , 2016, Dentistry journal.
[55] E. Wagner,et al. Chronic skin inflammation leads to bone loss by IL-17–mediated inhibition of Wnt signaling in osteoblasts , 2016, Science Translational Medicine.
[56] H. Takayanagi,et al. IL-17-producing γδ T cells enhance bone regeneration , 2016, Nature Communications.
[57] N. Dutzan,et al. Characterization of the human immune cell network at the gingival barrier , 2015, Mucosal Immunology.
[58] J. Fantasia. The Role of Antiangiogenic Therapy in the Development of Osteonecrosis of the Jaw. , 2015, Oral and maxillofacial surgery clinics of North America.
[59] S. Tetradis,et al. Pathophysiology of Osteonecrosis of the Jaws. , 2015, Oral and maxillofacial surgery clinics of North America.
[60] Liqing Yang,et al. Efficacy and Safety of Zoledronic Acid and Pamidronate Disodium in the Treatment of Malignant Skeletal Metastasis , 2015, Medicine.
[61] Jun Wang,et al. Systemic immunity shapes the oral microbiome and susceptibility to bisphosphonate-associated osteonecrosis of the jaw , 2015, Journal of Translational Medicine.
[62] J. Sayre,et al. Osteonecrosis of the Jaw Developed in Mice , 2015, The Journal of Biological Chemistry.
[63] A. Pabst,et al. In vitro effects of bisphosphonates on chemotaxis, phagocytosis, and oxidative burst of neutrophil granulocytes , 2014, Clinical Oral Investigations.
[64] G. Scagliotti,et al. Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors , 2014, Supportive Care in Cancer.
[65] J. Hodges,et al. Periodontal disease as a risk factor for bisphosphonate-related osteonecrosis of the jaw. , 2014, Journal of periodontology.
[66] Akinobu Matsumoto,et al. Zoledronic Acid Enhances Lipopolysaccharide-Stimulated Proinflammatory Reactions through Controlled Expression of SOCS1 in Macrophages , 2013, PloS one.
[67] S. Shi,et al. IL-17–Mediated M1/M2 Macrophage Alteration Contributes to Pathogenesis of Bisphosphonate-Related Osteonecrosis of the Jaws , 2013, Clinical Cancer Research.
[68] Joanne L Welton,et al. Monocytes and γδ T cells control the acute‐phase response to intravenous zoledronate: Insights from a phase IV safety trial , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[69] D. Kabelitz,et al. Defining the nature of human γδ T cells: a biographical sketch of the highly empathetic , 2012, Cellular and Molecular Immunology.
[70] L. Idolazzi,et al. Long-Term Effects of Amino-Bisphosphonates on Circulating γδ T Cells , 2012, Calcified Tissue International.
[71] V. Denaro,et al. Serum VEGF levels as predictive marker of bisphosphonate-related osteonecrosis of the jaw , 2012, Journal of Hematology & Oncology.
[72] P. Kostenuik,et al. Bench to bedside: elucidation of the OPG–RANK–RANKL pathway and the development of denosumab , 2012, Nature Reviews Drug Discovery.
[73] K. Gasser,et al. Drug-induced osteonecrosis of the jaw , 2012, memo - Magazine of European Medical Oncology.
[74] D. Carson,et al. Cutting Edge: Nitrogen Bisphosphonate-Induced Inflammation Is Dependent upon Mast Cells and IL-1 , 2012, The Journal of Immunology.
[75] R. Baron,et al. Denosumab and bisphosphonates: different mechanisms of action and effects. , 2011, Bone.
[76] A. Pabst,et al. Bisphosphonates affect migration ability and cell viability of HUVEC, fibroblasts and osteoblasts in vitro. , 2011, Oral diseases.
[77] T. Junt,et al. Th17 Cells, Not IL-17+ γδ T Cells, Drive Arthritic Bone Destruction in Mice and Humans , 2011, The Journal of Immunology.
[78] M. Pazianas. Osteonecrosis of the jaw and the role of macrophages. , 2011, Journal of the National Cancer Institute.
[79] E. Seeman,et al. Teriparatide therapy for alendronate-associated osteonecrosis of the jaw. , 2010, The New England journal of medicine.
[80] S. Hoefert,et al. Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings , 2010, Clinical Oral Investigations.
[81] R. Rizzoli,et al. Bisphosphonate-associated osteonecrosis of the jaw: a key role of inflammation? , 2009, Bone.
[82] C. Shuler,et al. Microbial biofilms in osteomyelitis of the jaw and osteonecrosis of the jaw secondary to bisphosphonate therapy. , 2009, Journal of the American Dental Association.
[83] J. Lo,et al. Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator. , 2009, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.
[84] L. Assael,et al. Comprehensive review of bisphosphonate therapy: implications for the oral and maxillofacial surgery patient. , 2009, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.
[85] L. Assael,et al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update. , 2009, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.
[86] R. Medzhitov. Origin and physiological roles of inflammation , 2008, Nature.
[87] N. Watts,et al. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy , 2008, Osteoporosis International.
[88] E. Elm,et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies , 2007, The Lancet.
[89] S. Pocock,et al. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies , 2007, BMJ : British Medical Journal.
[90] M. Rogers,et al. Molecular Mechanisms of Action of Bisphosphonates: Current Status , 2006, Clinical Cancer Research.
[91] A. Vecchione,et al. Bisphosphonates and oral cavity avascular bone necrosis: a review of twelve cases. , 2006, Anticancer research.
[92] T. Hansen,et al. Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis in comparison with infected osteoradionecrosis. , 2006, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.
[93] P. Clézardin,et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. , 2002, Cancer research.
[94] L. Devy,et al. Novel Antiangiogenic Effects of the Bisphosphonate Compound Zoledronic Acid , 2002, Journal of Pharmacology and Experimental Therapeutics.
[95] M. Rogers,et al. Bisphosphonates: from the laboratory to the clinic and back again. , 1999, Bone.
[96] S. Ruggiero. Medication-Related Osteonecrosis of the Jaw – 2022 Update , 2022 .
[97] I. Kaplan,et al. Comparison of the histopathological characteristics of osteomyelitis, medication-related osteonecrosis of the jaw, and osteoradionecrosis. , 2019, International journal of oral and maxillofacial surgery.
[98] C. Popescu,et al. Clinical, statistical, histological and immunohistochemical aspects of periodontal changes in patients with diabetes mellitus. , 2019, Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie.
[99] C. Busuioc,et al. Histological and immunohistochemical study on the apical granuloma. , 2018, Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie.
[100] T. Dodson,et al. Medication-Related Osteonecrosis of the Jaw—2014 Update , 2014 .
[101] T. Ikebe. Pathophysiology of BRONJ: Drug-related osteoclastic disease of the jaw , 2013 .
[102] American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. , 2007, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.
[103] L. Weeda. Drug induced osteonecrosis of the jaws. , 2006, The Journal of the Tennessee Dental Association.